From the Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Olympic-ro 33, Seoul 05505, Republic of Korea.
Radiology. 2019 Aug;292(2):440-446. doi: 10.1148/radiol.2019190133. Epub 2019 Jun 25.
Background Updated guidelines for suspected primary central nervous system lymphoma (PCNSL) are lacking. Purpose To investigate the diagnostic yield of initial systemic imaging in patients suspected of having PCNSL by using contrast material-enhanced chest and abdominopelvic CT and/or whole-body fluorine 18 fluorodeoxyglucose (FDG) PET/CT. Materials and Methods This retrospective study included 304 patients examined at a single tertiary hospital between January 1998 and October 2018. Consecutive adults (age >18 years) who were confirmed to have newly diagnosed PCNSL on the basis of findings at stereotactic brain biopsy were recruited. All patients were examined with contrast-enhanced chest and abdominopelvic CT and/or whole-body FDG PET/CT before initiation of PCNSL treatment. The diagnostic yield of CT and PET/CT was determined before therapy and at the time of recurrence in the brain. A χ test was performed to compare the diagnostic yield according to study date in order to assess for possible changes in technology during the study period. Results A total of 304 patients (180 men with a mean age [±standard deviation] of 58 years ± 13 and 124 women with a mean age of 59 years ± 13) were included. The diagnostic yield of CT and PET/CT for initial staging was 2% (six of 304 patients; 95% confidence interval [CI]: 0.7%, 4.3%), and these tests yielded false-positive findings in 13 of the 304 patients (4%; 95% CI: 2.3%, 7.2%). Diagnostic yield did not differ between patients evaluated before 2009 and those evaluated in 2009 and later ( = .82). The diagnostic yield of systemic imaging at recurrence was 1.5% (one of 68 patients; 95% CI: 0.0%, 7.9%), and these tests yielded false-positive findings in four of those 68 patients (6%; 95% CI: 1.6%, 14.4%). Conclusion Contrast-enhanced chest and abdominopelvic CT and/or whole-body fluorine 18 fluorodeoxyglucose PET/CT for initial staging, as well as for recurrence of suspected primary central nervous system lymphoma, had a low diagnostic yield. © RSNA, 2019 See also the editorial by Jara in this issue.
背景 目前缺乏疑似原发性中枢神经系统淋巴瘤(PCNSL)的更新指南。目的 本研究旨在通过对比增强胸部、腹部和盆腔 CT 和(或)全身氟 18 氟代脱氧葡萄糖(FDG)PET/CT 检查,探讨疑似 PCNSL 患者初始系统成像的诊断率。材料与方法 本回顾性研究纳入了 1998 年 1 月至 2018 年 10 月期间在一家三级医院接受检查的 304 例患者。连续纳入经立体定向脑活检证实为新发 PCNSL 的成年患者(年龄>18 岁)。所有患者在开始 PCNSL 治疗前均接受了增强胸部、腹部和盆腔 CT 和(或)全身 FDG PET/CT 检查。在治疗前和脑复发时评估 CT 和 PET/CT 的诊断率。为评估研究期间技术可能发生的变化,采用 χ2 检验比较不同研究时间的诊断率。结果 共纳入 304 例患者(男 180 例,平均年龄为 58 岁±13;女 124 例,平均年龄为 59 岁±13)。CT 和 PET/CT 对初始分期的诊断率为 2%(304 例患者中有 6 例;95%置信区间:0.7%,4.3%),304 例患者中有 13 例(4%;95%置信区间:2.3%,7.2%)出现假阳性结果。2009 年前和 2009 年后评估的患者之间,CT 和 PET/CT 的诊断率差异无统计学意义( =.82)。复发时全身成像的诊断率为 1.5%(68 例患者中有 1 例;95%置信区间:0.0%,7.9%),68 例患者中有 4 例(6%;95%置信区间:1.6%,14.4%)出现假阳性结果。结论 增强胸部、腹部和盆腔 CT 和(或)全身氟 18 氟代脱氧葡萄糖 PET/CT 检查用于初始分期以及疑似原发性中枢神经系统淋巴瘤的复发,其诊断率较低。